Study to Evaluate the Efficacy and Safety of HepaStem in Patients With Acute on Chronic Liver Failure (ACLF)
Status:
Recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
This is an interventional, double blind, randomized (2:1), and placebo-controlled study of 1
dose regimen of HepaStem in patients recently diagnosed (≤1 week) with ACLF grade 1 or 2 on
top of Standard of Care (SoC), and for whom the diagnosis is not resolved on the day of
infusion.